Pharmacokinetic properties and metabolism of a new potent antimalarial N-alkylamidine compound, M64, and its corresponding bioprecursors

European Journal of Pharmaceutical Sciences

Volumn 42, Issue 1-2, 2011, Pages 81-90

  Margout, Delphine ^a   Gattacceca, Florence ^a   Moarbess, Georges ^a   Wein, Sharon ^b   Ba, Christophe Tran Van ^b   Le Pape, Samuel ^a   Berger, Olivier ^c   Escale, Roger ^c   Vial, Henri J ^b   Bressolle, Franoise M M ^a  

^a UNIV MONTPELLIER   (France)

^b UNIVERSITÉ DE MONTPELLIER   (France)

^c UNIVERSITÉ DE MONTPELLIER   (France)

Author keywords

Antimalarial drugs; Bioprecursors; LC MS; Metabolism; N alkylamidine compound; Pharmacokinetics in rat

Indexed keywords

1,12 BIS( N,N' ACETAMIDINYL)DODECANE; 1,12 BIS( N,N' METHYLSULFONYLOXYACETAMIDINYL)DODECANE; ACETAMIDE DERIVATIVE; AMIDE; AMIDOXIME( 1,12 BIS( N,N' HYDROXYACETAMIDINYL)DODECANE; ANTIMALARIAL AGENT; M 64; M 64 DIACETAMIDE; M 64 MONOACETAMIDE; M 64 MONOAMIDOXIME; SULFONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIMALARIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG TRANSFORMATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY; LIVER MICROSOME; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; OXIDATION; PHARMACOLOGICAL PARAMETERS; PLASMODIUM FALCIPARUM; PLASMODIUM VINCKEI; PLASMODIUM VINCKEI INFECTION; PRIORITY JOURNAL; REDUCTION; SPECIES COMPARISON; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

ALKANES; AMIDINES; ANIMALS; ANTIMALARIALS; BIOTRANSFORMATION; CALIBRATION; HUMANS; INHIBITORY CONCENTRATION 50; MALARIA; MICE; MICROSOMES, LIVER; MOLECULAR STRUCTURE; OXIMES; PARASITIC SENSITIVITY TESTS; PLASMODIUM FALCIPARUM; PRODRUGS; RATS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SULFONIC ACIDS;

EID: 78650676564     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2010.10.012     Document Type: Article

References (42)

1. M.L. Ancelin, M. Calas, J. Bompart, G. Cordina, D. Martin, M. Ben Bari, and H. Vial Antimalarial activity of 77 phospholipid polar head analogs: close correlation between inhibition of phospholipid metabolism and in vitro Plasmodium falciparum growth Blood 91 1998 1426 1437
2. M.L. Ancelin, M. Calas, A. Bonhoure, S. Herbute, and H.J. Vial In vivo antimalarial activities of mono- and bis-quaternary ammonium salts interfering with Plasmodium phospholipid metabolism Antimicrob. Agents Chemother. 47 2003 2598 2605
3. M.L. Ancelin, M. Calas, V. Vidal-Sailhan, S. Herbute, P. Ringwald, and H.J. Vial Potent inhibitors of Plasmodium phospholipid metabolism with a broad spectrum of in vitro antimalarial activities Antimicrob. Agents Chemother. 47 2003 2590 2597
4. B.J. Berger, N.A. Naiman, J.E. Hall, J. Peggins, T.G. Brewer, and R.R. Tidwell Primary and secondary metabolism of pentamidine by rats Antimicrob. Agents Chemother. 36 1992 1825 1831
5. A.G. Biagini, E. Richier, P.G. Bray, M. Calas, H. Vial, and S.A. Ward Heme binding contributes to antimalarial activity of bis-quaternary ammoniums Antimicrob. Agents Chemother. 47 2003 2584 2589
6. U. Bronner, O. Ericsson, J. Nordin, I. Wikström, Y.A. Abdi, J.E. Hall, R.R. Tidwell, and L.L. Gustafsson Metabolism is an important route of pentamidine elimination in the rat: disposition of 14C-pentamidine and identification of metabolites in urine using liquid chromatography-tandem mass spectrometry Pharmacol. Toxicol. 77 1995 114 120
7. D.W. Boykin, A. Kumar, B.K. Bender, J.E. Hall, and R.R. Tidwell Anti-pneumocystis activity of bis-amidoximes and bis-O-alkylamidoximes prodrugs Bioorg. Med. Chem. Lett. 6 1996 3017 3020
8. F. Bressolle, M. Bromet-Petit, and M. Audran Validation of liquid chromatographic and gas chromatographic methods. Applications to pharmacokinetics J. Chromatogr. B: Biomed. Appl. 686 1996 3 10
9. M. Calas, G. Cordina, J. Bompart, M.B. Bari, T. Jei, M.L. Ancelin, and H. Vial Antimalarial activity of molecules interfering with Plasmodium falciparum phospholipid metabolism. Structure-activity relationship analysis J. Med. Chem. 40 1997 3557 3566
10. M. Calas, M.L. Ancelin, G. Cordina, P. Portefaix, G. Piquet, V. Vidal-Sailhan, and H. Vial Antimalarial activity of compounds interfering with Plasmodium falciparum phospholipid metabolism: comparison between mono- and bisquaternary ammonium salts J. Med. Chem. 43 2000 505 516
11. M. Calas, M. Ouattara, G. Piquet, Z. Ziora, Y. Bordat, M.L. Ancelin, R. Escale, and H. Vial Potent antimalarial activity of 2-aminopyridinium salts, amidines, and guanidines J. Med. Chem. 50 2007 6307 6315
12. V.I. Carrara, J. Zwang, E.A. Ashley, R.N. Price, K. Stepniewska, M. Barends, A. Brockman, T. Anderson, R. McGready, L. Phaiphun, S. Proux, M. van Vugt, R. Hutagalung, K.M. Lwin, A.P. Phyo, P. Preechapornkul, M. Imwong, S. Pukrittayakamee, P. Singhasivanon, N.J. White, and F. Nosten Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment PLoS One 4 2009 e4551
13. B. Clement, and W. Raether Amidoximes of pentamidine: synthesis, trypanocidal and leishmanicidal activity Arzneimittelforschung 35 1985 1009 1014
14. B. Clement, S. Schmitt, and M. Zimmermann Enzymatic reduction of bezamidoxime to benzamidine Arch. Pharm. 321 1988 955 956
15. B. Clement, M. Immel, R. Terlinden, F.J. Wingen, and W. Raether Amidoximes of pentamidine: synthesis, trypanocidal and leishmanicidal activity Arch. Pharm. 325 1992 61 62
16. B. Clement, M. Immel, S. Schmitt, and U. Steinmann Biotransformation of benzamidine and benzamidoxime in vivo Arch. Pharm. (Weinheim) 326 1993 807 812
17. B. Clement, and F. Jung N-hydroxylation of the antiprotozoal drug pentamidine catalyzed by rabbit liver cytochrome P-450 2C3 or human liver microsomes, microsomal retroreduction, and further oxidative transformation of the formed amidoximes. Possible relationship to the biological oxidation of arginine to NG-hydroxyarginine, citrulline, and nitric oxide Drug Metab. Dispos. 22 1994 486 497
18. B. Clement, and K. Lopian Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug Drug Metab. Dispos. 31 2003 645 651
19. B. Clement, A. Bürenheide, W. Rieckert, and J. Schwarz Diacetyldiamidoximeester of pentamidine, a prodrug for treatment of protozoal diseases: synthesis, in vitro and in vivo biotransformation Chem. Med. Chem. 1 2006 1260 1267
20. B. Davies, and T. Morris Physiological parameters in laboratory animals and humans Pharm. Res. 10 1993 1093 1095
21. R.E. Desjardins, C.J. Canfield, J.D. Haynes, and J.D. Chulay Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique Antimicrob. Agents Chemother. 16 1979 710 718
22. A.M. Dondorp, F. Nosten, P. Yi, D. Das, A.P. Phyo, J. Tarning, K.M. Lwin, F. Ariey, W. Hanpithakpong, S.J. Lee, P. Ringwald, K. Silamut, M. Imwong, K. Chotivanich, P. Lim, T. Herdman, S.S. An, S. Yeung, P. Singhasivanon, N.P. Day, N. Lindegardh, D. Socheat, and N.J. White Artemisinin resistance in Plasmodium falciparum malaria N. Engl. J. Med. 361 2009 455 467 Erratum in: N. Engl. J. Med. 2009. 361, 1714.
23. C. Farenc, J.R. Fabreguette, and F. Bressolle Pk-fit: a pharmacokinetic/pharmacodynamic and statistical data analysis software Comput. Biomed. Res. 33 2000 315 330
24. B.M. Greenwood, D.A. Fidock, D.E. Kyle, S.H. Kappe, P.L. Alonso, F.H. Collins, and P.E. Duffy Malaria: progress, perils, and prospects for eradication J. Clin. Invest. 118 2008 1266 1276
25. A. Hamzé, E. Rubi, P. Arnal, M. Boisbrun, C. Carcel, X. Salom-Roig, M. Maynadier, S. Wein, H. Vial, and M. Calas Mono-and bis-thiazolium salts have potent antimalarial activity J. Med. Chem. 48 2005 3639 3643
26. I. Marchi, S. Rudaz, M. Selman, and J.L. Veuthey Evaluation of the influence of protein precipitation prior to on-line SPE-LC-API/MS procedures using multivariate data analysis J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 845 2007 244 252
27. I. Midgley, K. Fitzpatrick, L.M. Taylor, S.J. Henderson, S.J. Wright, Z.R. Cybulski, B.A. John, A. McBurney, D.W. Boykin, and K.L. Trendler Pharmacokinetics and metabolism of the prodrug DB289 (2,5-bis[4-(N- methoxyamidino)phenyl]furan monomaleate) in rat and monkey and its conversion to the antiprotozoal/antifungal drug DB75 (2,5-bis(4-guanylphenyl)furan dihydrochloride) Drug Metab. Dispos. 35 2007 955 967
28. M. Ouattara, S. Wein, M. Calas, Y.V. Hoang, H. Vial, and R. Escale Synthesis and antimalarial activity of new 1, 12-bis(N,N′-acetamidinyl) dodecane derivatives Bioorg. Med. Chem. Lett. 17 2007 593 596
29. M. Ouattara, S. Wein, S. Denoyelle, S. Ortial, T. Durand, R. Escale, H. Vial, and Y. Vo-Hoang Design and synthesis of amidoxime derivatives for orally potent C-alkylamidine-based antimalarial agents Bioorg. Med. Chem. Lett. 19 2009 624 626
30. RDPP, 1999. Pk-fit Computer Program, Version 2.1. RDPP, Montpellier, France.
31. X.J. Salom-Roig, A. Hamze, M. Calas, and H.J. Vial Dual molecules as new antimalarials Comb. Chem. High Throughput Screen. 8 2005 49 62
32. J.Y. Saulter, J.R. Kurian, L.A. Trepanier, R.R. Tidwell, A.S. Bridges, D.W. Boykin, C.E. Stephens, M. Anbazhagan, and J.E. Hall Unusual dehydroxylation of antimicrobial amidoxime prodrugs by cytochrome b5 and NADH cytochrome b5 reductase Drug Metab. Dispos. 33 2005 1886 1893
33. W. Trager, and J.B. Jensen Human malaria parasites in continuous culture Science 193 1976 673 675
34. US Food and Drug Administration, 2001. Guidance for industry. Bioanalytical method validation. http://www.fda.gov/cder/guidance/index.htm (accessed May 2004).
35. H.J. Vial, and M. Calas Inhibitors of phospholipid metabolism P. Rosenthal, Antimalarial Chemotherapy, Mechanisms of Action, Modes of Resistance, and New Directions in Drug Development 2001 Humana Press Totowa 347 365
36. H. Vial, P. Eldin, L. Tielens, and J. van Hellemond Mol. Biochem. Parasitol. 126 2003 143 154
37. H.J. Vial, S. Wein, C. Farenc, C. Kocken, O. Nicolas, M.L. Ancelin, F. Bressolle, A. Thomas, and M. Calas Precursors of bisthiazolium are potent antimalarials Proc. Natl. Acad. Sci. U.S.A. 101 2004 15458 15463
38. C.T. Viswanathan, S. Bansal, B. Booth, A.J. DeStefano, M.J. Rose, J. Sailstad, V.P. Shah, J.P. Skelly, P.G. Swann, and R. Weiner Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays Pharm. Res. 24 2007 1962 1973 (Pubitemid 47389236)
39. K. Wengelnik, V. Vidal, M.L. Ancelin, A.M. Cathiard, J.L. Morgat, C.H. Kocken, M. Calas, S. Herrera, A.W. Thomas, and H.J. Vial Science 295 2002 1311 1314
40. T. Weller, L. Alig, M. Beresini, B. Blackburn, S. Bunting, P. Hadvary, M.H. Muller, D. Knopp, B. Levet-Trafit, M.T. Lipari, N.B. Modi, M. Muller, C.J. Refino, M. Schmitt, P. Schonholzer, S. Weiss, and B. Steiner Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines J. Med. Chem. 39 1996 3139 3147
41. World Health Organisation (WHO), 2008. World Malaria Report 2008. http://www.who.int/malaria/wmr2008/ (accessed march 2009).
42. X. Xu, H. Mei, S. Wang, Q. Zhou, G. Wang, L. Broske, A. Pena, and W.A. Korfmacher A study of common discovery dosing formulation components and their potential for causing time-dependent matrix effects in high-performance liquid chromatography tandem mass spectrometry assays Rapid Commun. Mass Spectrom. 19 2005 2643 2650